BACKGROUND: Although previous studies have noted an increased risk of colorectal cancer (CRC) among moderate to heavy alcohol consumers in comparison with nondrinkers, the relation between alcohol consumption and CRC survival remains unclear. METHODS: Cases of incident invasive CRC diagnosed between 1997 and 2007 were identified via population-based cancer registries at 4 study sites in the Colon Cancer Family Registry. Study participants completed a risk-factor questionnaire on prediagnostic behaviors, including wine, beer, and liquor consumption, at the baseline. Prospective follow-up for survival was conducted for 4966 CRC cases. Cox regression was used to compare nondrinkers with individuals who consumed, on average, 1 or more servings of alcohol per day in the years preceding their CRC diagnosis with respect to overall and disease-specific survival. Separate analyses by beverage type, stratified by patient and tumor attributes, were also performed. All models were adjusted for the age at diagnosis, sex, study site, year of diagnosis, smoking history, body mass index, and education. RESULTS: Prediagnostic beer and liquor consumption was not associated with CRC survival; however, higher levels of wine consumption were modestly associated with a better prognosis overall (CRC-specific hazard ratio [HR], 0.70, 95% confidence interval [CI], 0.48-1.03; overall HR, 0.70; 95% CI, 0.53-0.94). Similar patterns were noted in stratified analyses. CONCLUSIONS: These findings suggest that prediagnostic wine consumption is modestly associated with more favorable survival after CRC.
INTRODUCTION
Colorectal cancer (CRC) remains a leading cause of cancer death in the United States. 1 Advances in early detection have contributed to favorable 5-year relative survival (90%) for patients with localized CRC; however, the survival rate with distant-stage disease is only 13%. 1 Thus, it is important to identify factors contributing to the prognosis of CRC. Alcohol has been classified as a class 1 carcinogen, and the role of alcohol consumption as an etiologic risk factor for CRC has been well-characterized. [2] [3] [4] [5] Previous studies have also noted a greater likelihood of advanced CRC at diagnosis and an increased risk of liver metastases among heavy drinkers. [6] [7] [8] However, evidence for a possible relation between alcohol and CRC survival has been minimal, with the few existing studies finding suggestive but not statistically significant evidence for an association between overall prediagnostic alcohol consumption and the prognosis of CRC. [9] [10] [11] [12] Pelser et al 12 recently reported that moderate alcohol intake, in comparison with little or no alcohol consumption, was associated with a lower risk of all-cause mortality among CRC patients. Other studies have also observed patterns in the relation between recent prediagnostic alcohol consumption and CRC outcomes that differ by beverage type. [9] [10] [11] We conducted an analysis of data from the Colon Cancer Family Registry (C-CFR) to determine whether survival among individuals diagnosed with CRC varied according to patterns of prediagnostic alcohol consumption overall, by beverage type, and across case groups defined by patient and tumor attributes.
MATERIALS AND METHODS

Study Population
The study sample included women and men diagnosed with incident invasive CRC between January 1997 and June 2007 who participated in the C-CFR. The C-CFR is an international, collaborative effort of investigators in Australia, Canada, and the United States with 6 contributing study centers. C-CFR recruitment protocols and eligibility criteria have been previously detailed. 13 We restricted our analysis to population-based cases, not selected on the basis of family history, who were recruited through cancer registries at 1 of 4 sites (University of Melbourne [ 
Alcohol Consumption Assessment
Study participants completed a standardized risk-factor questionnaire regarding prediagnostic exposures via telephone interviews or mail at the time of enrollment (http://www.coloncfr.org/questionnaires).
Interviews were administered an average of 11.4 months (median, 9.4 months) after the diagnosis. Participants recalled their alcohol consumption before the CRC diagnosis between the ages of 20 and 30 years, between the ages of 30 and 50 years, and after the age of 50 years (as applicable). Participants were queried about whether they had consumed 1 or more servings per week of alcohol for a period of 6 months or longer, and they were separately asked whether they had consumed 1 or more servings per week of beer or hard cider, wine or fortified wines, or hard liquor for 6 months or longer. A serving was defined as a 12-oz can or bottle of beer or cider, a 4-oz glass of wine or 1-oz glass of fortified wine, or a 1-oz shot of hard liquor. For each beverage category, participants reported their average servings per week and the number of years within the age interval during which they drank that beverage. To reflect recent prediagnostic consumption, we restricted our analysis to intake during the age interval including the age at diagnosis (here called prediagnostic alcohol consumption). 14 We further categorized alcohol intake as average alcohol use overall and by alcoholic beverage type.
Tumor Characteristics
Cancers arising from the cecum through the splenic flexure (International Classification of Diseases for Oncology, 3rd Edition codes C180 and C182-C185) were grouped together as right-sided colon cancers, whereas neoplasms in the descending or sigmoid colon (C186-C187) were defined as left-sided colon cancers. Tumors originating in the rectosigmoid junction (C199) or rectum (C209) were classified as rectal cancers. 15 We assessed mismatch repair (MMR) status with 1 of 2 methods. 13 The first method was genetic analysis for microsatellite instability based on a 10-marker panel using tumor DNA and DNA from normal surrounding tissue. 10 We categorized tumors as MMR-deficient (ie, high microsatellite instability) if instability was observed for 30% of the markers and as MMR-proficient (ie, microsatellite stability) if instability was seen in <30% of the markers. For a subset of cases, we evaluated MMR status with the immunohistochemistry of 4 markers. 16 Cases with tumors in which all markers exhibited positive staining were categorized as proficient; tumors with 1 or more negative markers were classified as deficient. We assayed tumors for the presence of the V600E BRAF mutation with a fluorescent allele-specific polymerase chain reaction. 17 CpG island methylator phenotype (CIMP) testing was based on a validated 5-gene panel quantitative DNA methylation assay, and it was completed for cases with complete MMR information diagnosed before July 2002. Cases were classified as CIMP-high if the percentage-ofmethylated-reference ratio was 10 for 3 of 5 markers in a tumor and as non-CIMP if the percentage-ofmethylated-reference ratio was 10 for < 3 markers. 18 
Vital Status and Cause of Death
We ascertained the vital status and date and cause of death via linkage to population-based registries, contact with relatives, and the collection of death certificates. For a small number of cases, we determined the vital status through other means (eg, obituaries). 19 We categorized a death as CRC-specific when the underlying cause of death was classified as C18.0-C20.0 or C26.0 (International Classification of Diseases, Tenth Revision). Vital status information was available through December 2013. Cases who were alive through the most recent evaluation of the vital status were censored at that date.
Statistical Analysis
We used Cox proportional hazards regression to assess the relation of prediagnostic alcohol consumption with overall and CRC-specific survival. Our timescale was defined as days since the CRC diagnosis, with left censoring to account for the time lag between diagnosis and C-CFR enrollment. Separate analyses were conducted for each outcome. In analyses of CRC-specific survival, we censored participants who died from causes other than CRC. Proportional hazards assumptions were supported via testing for a nonzero slope of the scaled Schoenfeld residuals on ranked failure times.
Original Article
We conducted separate analyses for alcohol overall and by beverage type. We used as the reference category nondrinkers, including those who consumed an average of less than 1 serving of alcohol per week. We also conducted analyses stratified by sex, age at diagnosis, smoking history, tumor site, BRAF-mutation status, MMR status, and CIMP status.
We adjusted all regression models for the age at diagnosis, year of diagnosis, sex, study site, and several self-reported prediagnostic exposures ascertained during the baseline interview: smoking history, body mass index, educational attainment, and use of nonsteroidal anti-inflammatory drugs. All covariates were categorized as shown in Table 1 . We conducted all analyses with Stata SE 14 (StataCorp, College Station, Texas).
RESULTS
Compared with individuals who consumed less than 1 serving of alcohol per week, individuals in the upper alcohol consumption category (more than 1 serving per day) were more likely to be male (78% vs 38%), to have a history of smoking (74% vs 48%), and to have a primary tumor in the rectum (40% vs 33%) and were less likely to be obese (23% vs 31%) or to have a primary tumor that was MMR-deficient (10% vs 16%) or CIMP-high (9% vs 17%; Table 1 ). The distribution of participant characteristics was similar among persons in the middle and upper consumption categories except for sex (male, 53% vs 78%) and smoking status (current smokers, 15% vs 28%). After adjustments for patient and tumor characteristics, there was no evidence of a relation between overall prediagnostic alcohol consumption and survival (Table  2) . With respect to specific alcohol types, evidence of modest but not statistically significant poorer overall survival was noted in those who consumed more than 1 serving of liquor per day versus those who consumed less than 1 serving per week (overall hazard ratio [HR], 1.12; 95% confidence interval [CI], 0.92-1.36). Conversely, there was evidence of an inverse association of wine consumption with survival. This relation was primarily evident in the upper category of wine consumption (CRC-specific HR, 0.70; 95% CI, 0.48-1.03; overall HR, 0.70; 95% CI, 0.53-0.94).
When we focused our analyses on prediagnostic wine consumption, we observed generally similar findings within case subgroups (Tables 3 and 4 ). This association, strongest in the upper wine consumption category, was statistically significant only in men (CRC-specific HR, 0.57; 95% CI, 0.34-0.97; overall HR, 0.61; 95% CI, 0.42-0.90) and in former smokers (CRC-specific HR, 0.59; 95% CI, 0.36-0.98; overall HR, 0.62; 95% CI, 0.42-0.91). There was some difference in the association depending on the CRC site, with the strongest inverse relation noted among cases with left-sided colon tumors (CRC-specific HR, 0.44; 95% CI, 0.20-0.963; overall HR, 0.59; 95% CI, 0.33-1.02). Conversely, we noted that current smokers who were modest wine drinkers displayed a poorer prognosis than individuals who consumed less than 1 serving per week (CRC-specific HR, 1.80; 95% CI, 1.21-2.67; overall HR, 1.41; 95% CI, 1.00-1.98).
DISCUSSION
In this prospective analysis of invasive CRC, there was no evidence for an association between overall prediagnostic alcohol consumption and disease survival. When we considered different types of beverage types, however, our findings suggested slightly better survival with higher levels of prediagnostic wine consumption, especially in men and former smokers. Adjusted for the age at diagnosis, year of diagnosis, sex, smoking history, body mass index, education, and study site. Adjusted for the age at diagnosis, year of diagnosis, sex, smoking history, body mass index, education, and study site. Consistent with the results presented here, the majority of previous studies have found no evidence for a relation between prediagnostic alcohol consumption overall and CRC outcomes. In the largest evaluation of this association to date, Pelser et al 12 reported findings similar to ours in that they found a suggestively but not significantly lower risk of all-cause mortality when they compared moderate drinkers with nondrinkers (colon cancer relative risk [RR], 0.86; 95% CI, 0.73-1.01; rectal cancer RR, 0.84; 95% CI, 0.62-1.14). Among colon cancer cases specifically, this observed relation was likely primarily driven by the association between prediagnostic alcohol intake and lower cardiovascular disease mortality (colon cancer RR, 0.47; 95% CI, 0.31-0.73). In a previous analysis of a subset of the data included in the current analysis, Phipps et al 10 similarly found no association between overall alcohol consumption and CRC outcomes; although that study also considered separate associations with prediagnostic wine, beer, and liquor consumption, results were inconclusive because of small numbers.
Two of the 3 prior studies performing separate evaluations by beverage type observed statistically significant findings indicating a more favorable prognosis for those with higher prediagnostic wine intake.
9-11 Zell et al 11 reported a significant association between overall survival and regular wine intake (1-3 glasses per month) versus infrequent wine intake (<1 glass per month) among CRC patients with a family history of CRC (HR, 0.50; 95% CI, 0.25-0.99). In addition, a recent study by Phipps et al. 9 found significantly better overall survival among stage III colon cancer cases reporting 30 or more servings of wine per month in the year before their cancer diagnosis (HR vs never consumers, 0.51; 95% CI, 0.30-0.85), and they found no evidence for variations in the effect of prediagnostic alcohol use on CRC outcomes according to evaluated tumor characteristics. This result and our similar findings could have been affected by low numbers, especially within wine-only analyses, but they may also suggest that the impact of alcohol consumption on disease progression or development does not depend on known molecular pathways of disease process.
Consistent with recent meta-analyses indicating a positive association between alcohol consumption and CRC risk, 3, 4 in vitro evidence suggests that high alcohol consumption, perhaps via its mechanism as a local solvent, plays a role in early tumorigenesis in the colon and rectum. 20 Alcohol damages the epithelial cells of the intestinal tract through direct and indirect means: it assists the absorption of acetaldehyde, a recognized carcinogen, and facilitates the production of species that proliferate DNA damage, oxidative stress, and lipid peroxidation in the intestinal lumen. 20 Increased alcohol intake can also lead to suppression of immune surveillance, which could affect both CRC risk and progression. 20 Our results indicated no association between overall prediagnostic alcohol consumption and survival but also hinted at a potentially less favorable prognosis with higher daily liquor intake.
Conversely, recent evidence suggests that moderate wine consumption may elicit benefits not only for cardiovascular disease survival but also for CRC prognosis. 21 With respect to cardiovascular outcomes, moderate wine consumption has been linked to lower levels of inflammatory markers. 22 Red wine also contains resveratrol and polyphenols, elements that appear to exhibit anticoagulatory, 23 anti-oxidant, 24 and antiplatelet traits. 21 However, whether and how these properties contribute to CRC survival is unclear. 11, 25 Studies using mice found that resveratrol triggered apoptosis in cancer cell lines, 26 downregulated intestinal genes involved in cell proliferation or cell cycle progression, 27 interrupted the growth of transplanted human primary gastric cancer cells, 28 and intensified the antitumor effect of 5-fluorouracil. 29 Thus, it is plausible that our findings reflect some CRC-specific effects of wine.
The interpretation of these findings is subject to some limitations. Our measure of alcohol consumption required self-reported recall for a time period before the CRC diagnosis. By relying on this variable, we assumed that patient recall was accurate. Furthermore, because our measure of alcohol intake could reflect an averaged consumption level over an extended time (eg, ages of 30-50 years for someone diagnosed at the age of 50 years), there is potential for misclassification of the relevant exposure. In addition, despite the large size of our overall study, wine-specific analyses stratified by tumor markers lacked the statistical precision necessary to conclude differences between MMR, CIMP, and BRAF-mutation strata. We also had limited information on the stage at diagnosis in our sample; however, when we performed a sensitivity analysis stratified by the tumor stage among those with these data, our findings and interpretations did not change. Finally, our findings may be partially attributable to lifestyle differences between individuals who regularly consume wine and nonconsumers. Past evidence indicates that wine consumption is positively associated with a healthier diet, 30 physical activity, 30 educational attainment, 31 and income, 31 all of which may also be associated with CRC survival. Although we did adjust for several patient characteristics, residual confounding is possible. This study is among the first to focus on the relation between prediagnostic alcohol consumption, overall and by type, and CRC outcomes with population-based data. In line with past findings, we observed that overall prediagnostic alcohol use was not associated with overall or disease-specific survival but also that higher levels of prediagnostic wine consumption were associated with a more favorable prognosis. Because the mechanistic action of wine on the prognosis of CRC is not understood, further study is merited to better elucidate biological pathways and explore possible alternative explanations.
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